Extending Life. Redefining Heart Valve Replacement.
LevTech Lifesciences is transforming the future of heart valve replacement with next-generation polymeric heart valves — designed to last longer and free patients from the risks of lifelong anticoagulant therapy.
LevTech polymeric heart valves are investigational and are not available for commercial sale. They have not been approved or cleared by any regulatory authorities, including the US FDA. Their clinical safety and efficacy have not yet been demonstrated.
Future of Heart Valve Replacement
Polymeric Heart Valves
Extending Life. Redefining Heart Valve Replacement.
LevTech Lifesciences is transforming the future of heart valve replacement with next-generation polymeric heart valves — designed to last longer and free patients from the risks of lifelong anticoagulant therapy.
Future of Heart Valve Replacement
Polymeric Heart Valves
LevTech polymeric heart valves are investigational and are not available for commercial sale. They have not been approved or cleared by any regulatory authorities, including the US FDA. Their clinical safety and efficacy have not yet been demonstrated.
1 in 4
Heart valve patients will need repeat surgeries in their lifetime.
A Challenge in Cardiac Care
Every year, millions rely on heart valve replacements to survive — yet traditional valves can require patients to take anticoagulants for life or to undergo multiple re-operations. These shortcomings bring ongoing health risks, lifestyle restrictions, and high treatment costs.
For younger patients especially, the need for multiple valve replacements over a lifetime is a reality that impacts long-term health outcomes and quality of life.
Contact us to learn more.
Where Science Meets Human Impact
Our technology involves novel materials, innovative design and automated manufacturing.
Proprietary polymeric materials
uniquely synthesised to withstand blood clot formation, calcification, and biodegradation.
Innovative designs
optimised through computational modelling to maximize hydrodynamic performance for various patient groups
Automated manufacturing
that enables scalability, product diversity, short production time, and high precision.
The image is representational only. It does not depict the actual device.
Proprietary polymeric materials
uniquely synthesised to withstand blood clot formation, calcification, and biodegradation.
Innovative designs
optimised through computational modelling to maximize hydrodynamic performance for various patient groups
Automated manufacturing
that enables scalability, product diversity, short production time, and high precision.
The image is representational only. It does not depict the actual device.
Global Expertise. Unified Purpose.
At LevTech, innovation is driven by leaders in materials science, surgery, and business strategy:
Dr. David S. Winlaw
Director
Renowned cardiothoracic and neonatal surgeon with decades of patient-focused innovation.
Our collaborators, partners, and supporters
Our research and development are supported by respected institutions, government agencies, and global healthcare partners — a testament to the credibility and potential of our mission.
Changing Lives, One Heart at a Time
Behind every innovation is a human story. For patients facing a lifetime of repeat surgeries or the risks of daily anticoagulants, our work represents more than technology — it represents hope, freedom, and a better quality of life.
“A daily reminder of my condition. A future without that worry would be incredible, not just for me, but for every patient who wants to live without those limits.”
"Anticoagulants kept me alive, but they also kept me from living the life I wanted. I had to give up sports, certain travel plans, and even simple things like hiking because of the bleeding risk. The medication was always on my mind — a daily reminder of my condition. A future without that worry would be incredible, not just for me, but for every patient who wants to live without those limits."
“The idea of a valve that could last decades, without the need for daily blood-thinning medication, changes everything for people like me.”
"I’ve had two valve replacements already, and I’m only 35. Each surgery meant months of recovery, anxiety, and the constant fear that it would happen again. The idea of a valve that could last decades — without the need for daily blood-thinning medication — changes everything for people like me. It means less time in hospital, fewer risks, and more years of truly living my life."
“Knowing there’s research focused on making his life easier — a valve that could grow with him and last longer — gives us hope we didn’t have before.”
"As a parent, I worry about what my son will go through as he grows older with a mechanical valve. He’s already endured more than most children should. Right now, I know he’ll face more surgeries and the lifelong challenge of anticoagulants. Knowing there’s research focused on making his life easier — a valve that could grow with him and last longer — gives us hope we didn’t have before."
“It’s wonderful to see the results of medical innovations with patients like Meilani. From a developmental and emotional standpoint, she really is thriving.”
When Ashley heard that her newborn daughter, Meilani, had Tetralogy of Fallot, it came as a shock. Over the years, Meilani underwent multiple open-heart procedures, including surgeries to place and later replace a bioprosthetic valve conduit to match her growing anatomy. Now a thriving 11-year-old who loves skateboarding, Meilani aspires to become a Child Life Specialist to help kids like her. Stories like hers highlight the vital need for next-generation polymeric heart valves—offering young patients longer-lasting solutions, fewer repeat open-heart operations, and a fuller life ahead.
“A daily reminder of my condition. A future without that worry would be incredible, not just for me, but for every patient who wants to live without those limits.”
"Anticoagulants kept me alive, but they also kept me from living the life I wanted. I had to give up sports, certain travel plans, and even simple things like hiking because of the bleeding risk. The medication was always on my mind — a daily reminder of my condition. A future without that worry would be incredible, not just for me, but for every patient who wants to live without those limits."
“The idea of a valve that could last decades, without the need for daily blood-thinning medication, changes everything for people like me.”
"I’ve had two valve replacements already, and I’m only 35. Each surgery meant months of recovery, anxiety, and the constant fear that it would happen again. The idea of a valve that could last decades — without the need for daily blood-thinning medication — changes everything for people like me. It means less time in hospital, fewer risks, and more years of truly living my life."
“Knowing there’s research focused on making his life easier — a valve that could grow with him and last longer — gives us hope we didn’t have before.”
"As a parent, I worry about what my son will go through as he grows older with a mechanical valve. He’s already endured more than most children should. Right now, I know he’ll face more surgeries and the lifelong challenge of anticoagulants. Knowing there’s research focused on making his life easier — a valve that could grow with him and last longer — gives us hope we didn’t have before."
“It’s wonderful to see the results of medical innovations with patients like Meilani. From a developmental and emotional standpoint, she really is thriving.”
When Ashley heard that her newborn daughter, Meilani, had Tetralogy of Fallot, it came as a shock. Over the years, Meilani underwent multiple open-heart procedures, including surgeries to place and later replace a bioprosthetic valve conduit to match her growing anatomy. Now a thriving 11-year-old who loves skateboarding, Meilani aspires to become a Child Life Specialist to help kids like her. Stories like hers highlight the vital need for next-generation polymeric heart valves—offering young patients longer-lasting solutions, fewer repeat open-heart operations, and a fuller life ahead.
As Featured In
Our work has been recognised by leading medical institutions, research organisations, and media outlets for its potential to transform cardiac care.
LevTech Secures Major Funding to Advance Polymeric Heart Valve Trials to Advance Robotic Fabrication of Polymeric Heart Valves
A significant investment from NSW Government will accelerate LevTech’s path toward clinical testing, bringing its life-changing heart valve technology closer to patients.
Pioneering Materials Science Meets Medical Device Innovation
In a recent media coverage, LevTech’s proprietary surface modification technology was featured highlighting its potential to overcome decades-old limitations in heart valve replacements.
Sydney Solutions: A Celebration of Research Translation at the University of Sydney
In a recent event at the University of Sydney, LevTech shared its journey of research translation in a panel discussion.
LevTech Secures Major Funding to Advance Polymeric Heart Valve Trials to Advance Robotic Fabrication of Polymeric Heart Valves
A significant investment from NSW Government will accelerate LevTech’s path toward clinical testing, bringing its life-changing heart valve technology closer to patients.
Pioneering Materials Science Meets Medical Device Innovation
In a recent media coverage, LevTech’s proprietary surface modification technology was featured highlighting its potential to overcome decades-old limitations in heart valve replacements.
Sydney Solutions: A Celebration of Research Translation at the University of Sydney
In a recent event at the University of Sydney, LevTech shared its journey of research translation in a panel discussion.
Investing in a Healthier Future
LevTech Lifesciences is at the forefront of a breakthrough in heart valve technology. As we advance toward clinical milestones, we are seeking visionary investors and collaborators to join us in shaping the next era of cardiac care.